Anton C. Bizzell M.D.
Anton C. Bizzell, M.D., President and CEO of The Bizzell Group, has more than 25 years of combined clinical, research, health services, policy and management experience with various private and public organizations and agencies within Health and Human Services (HHS), including Substance Abuse and Mental Health Services Administration (SAMHSA) and National Institutes of Health (NIH). He has focused his career on public health issues related to access, quality, and evidence-based medical and behavioral health services.
Dr. Bizzell has led efforts in the area of prescription drug use and substance use disorders for SAMHSA, which included collaborating with other federal agencies such as NIH, the Food and Drug Administration (FDA), the Drug Enforcement Administration (DEA), the White House Office of National Drug Control Policy, and other federal, national, state and professional organizations. In addition, he provided medical and clinical advice for the 1600 methadone treatment programs in the U.S. and oversaw national regulatory and educational efforts on buprenorphine, a medication-assisted treatment for individuals dependent on prescription drugs containing opioids.